Read by QxMD icon Read


shared collection
147 papers 25 to 100 followers
By Eduardo Roque Cardiologista com foco em cardiologia hospitalar e cuidados intensivos. Professor de clínica médica.
Denise Hilfiker-Kleiner, Hossein Ardehali, Rodolphe Fischmeister, Paul Burridge, Emilio Hirsch, Alexander R Lyon
No abstract text is available yet for this article.
February 7, 2019: European Heart Journal
Amanda W Cai, Marian H Taylor, Bhavadharini Ramu
PURPOSE OF REVIEW: The number of cancer survivors is increasing, and cardiovascular events are a significant cause of morbidity and mortality in these patients. Preexisting cardiovascular conditions as well as the development of cancer therapeutics-related cardiac dysfunction (CTRCD), in particular left ventricular dysfunction and heart failure, limit the options for cancer therapies for these patients and contribute to reduced cancer survival. RECENT FINDINGS: Recent guidelines and position statements from various cardiology and oncology societies provide an outline for the practicing physician for the management of CTRCD...
February 11, 2019: Current Opinion in Cardiology
William A E Parker, Rachel C Orme, Jessica Hanson, Hannah M Stokes, Claire M Bridge, Patricia A Shaw, Wael Sumaya, Kirstie Thorneycroft, Giovanna Petrucci, Benedetta Porro, Heather M Judge, Ramzi A Ajjan, Bianca Rocca, Robert F Storey
Higher aspirin doses may be inferior in ticagrelor-treated acute coronary syndrome (ACS) patients and reducing bleeding risk whilst maintaining antithrombotic benefits could improve outcomes. We characterized the pharmacodynamics of a novel dual-antiplatelet-therapy regimen consisting of very-low-dose twice-daily (BD) aspirin with standard-dose ticagrelor. A total of 20 ticagrelor-treated ACS patients entered a randomized crossover to take aspirin 20 mg BD (12-hourly) during one 14-day period and 75 mg once-daily (OD) in the other...
February 13, 2019: Platelets
Dalene M Bott-Kitslaar, Robert D McBane, Ana I Casanegra, Damon E Houghton, David A Froehling, Danielle T Vlazny, Aneel A Ashrani, David O Hodge, Emily R Vargas, Matthew A Bartlett, Rayya A Saadiq, Paul R Daniels, Raymond C Shields, Charles J Lenz, Teresa R Lang, Waldemar E Wysokinski
OBJECTIVE: To compare the clinical efficacy and safety of apixaban with those of rivaroxaban for the treatment of acute venous thromboembolism (VTE). PATIENTS AND METHODS: Consecutive patients enrolled in the Mayo Thrombophilia Clinic Registry (between March 1, 2013, and January 30, 2018) and treated with apixaban or rivaroxaban for acute VTE were followed forward in time. The primary efficacy outcome was VTE recurrence. The primary safety outcome was major bleeding; the second safety outcome was clinically relevant nonmajor bleeding (CRNMB); and the third was a composite of major bleeding or CRNMB...
February 6, 2019: Mayo Clinic Proceedings
Dalia Di Nunzio, Antonino Recupero, Cesare de Gregorio, Concetta Zito, Scipione Carerj, Gianluca Di Bella
PURPOSE OF REVIEW: The aim is to provide a description of the most important echocardiographic features in systemic amyloidosis. RECENT FINDINGS: Amyloidosis is a heterogeneous group of multisystem disorders, characterized by an extracellular deposition of amyloid fibrils. Several imaging tests are available for the diagnosis; however, echocardiography is the cornerstone of the non-invasive imaging modality for cardiac amyloidosis. So far, little is known about the diagnosis of cardiac amyloidosis through imaging modalities...
February 12, 2019: Current Cardiology Reports
Dinu Valentin Balanescu, Dominique J Monlezun, Teodora Donisan, David Boone, Frances Cervoni-Curet, Nicolas Palaskas, Juan Lopez-Mattei, Peter Kim, Cezar Iliescu, Serban Mihai Balanescu
OBJECTIVES: Cancer has been proposed as a cardiovascular risk factor. We aimed to assess the cardiovascular risk profile and coronary angiography (CA) findings of cancer patients and compare them to those of patients without cancer. METHODS: A retrospective case-control analysis was conducted on randomly enrolled cancer and non-cancer patients from a high-volume cardio-oncology center and a tertiary cardiology center, respectively, who underwent CA from April 2008 to June 2018...
January 2019: Journal of Invasive Cardiology
Margot K Davis, Sean A Virani
No abstract text is available yet for this article.
December 26, 2018: Canadian Journal of Cardiology
Jorie Versmissen, Katrina M Mirabito Colafella, Stijn L W Koolen, A H Jan Danser
No abstract text is available yet for this article.
February 6, 2019: Cardiovascular Research
Timothy M Markman, Maurie Markman
Traditional chemotherapeutic agents and newer targeted therapies for cancer have the potential to cause cardiovascular toxicities. These toxicities can result in arrhythmias, heart failure, vascular toxicity, and even death. It is important for oncologists and cardiologists to understand the basic diagnostic and management strategies to employ when these toxicities occur. While anti-neoplastic therapy occasionally must be discontinued in this setting, it can often be maintained with caution and careful monitoring...
2019: F1000Research
Mazen Hanna, Chetan Huded, E Rene Rodriguez, Dermot Phelan, Deborah Kwon, Wael Jaber, Jason Valent, Michael Zhen-Yu Tong
The last decade has seen major advances in diagnosing and treating cardiac amyloidosis. Early diagnosis can often now be made using noninvasive laboratory testing and imaging. New treatments are effective and well tolerated.
January 2019: Cleveland Clinic Journal of Medicine
Christina Binder, Franz Duca, Philipp Dominik Stelzer, Christian Nitsche, René Rettl, Stefan Aschauer, Andreas A Kammerlander, Thomas Binder, Hermine Agis, Renate Kain, Christian Hengstenberg, Julia Mascherbauer, Diana Bonderman
Aims: Cardiac amyloidosis (CA) leads to signs and symptoms of heart failure (HF). The mechanisms of biventricular dysfunction and their impact on outcome in subtypes of CA are poorly understood. Our aim was to compare right ventricular (RV) and left ventricular (LV) parameters in patients with light chain (AL) and wild-type transthyretin amyloidosis (ATTRw) and evaluate their ability to predict cardiac outcome. Methods and results: We included patients with CA into a prospective registry...
January 10, 2019: European Heart Journal Cardiovascular Imaging
Matthias Totzeck, Martin Schuler, Martin Stuschke, Gerd Heusch, Tienush Rassaf
Current therapy of advanced cancers is based on several modalities including radiotherapy, cytotoxic chemotherapy, molecularly targeted inhibitors and antibodies targeting immune checkpoints. All of those these modalities can negatively impact the cardiovascular system, and there is considerable experience in relation to radiotherapy and chemotherapy. In contrast, the knowledge base on cardiovascular toxicities of novel agents targeting signal transduction pathways and immune regulation is quite limited. In particular, potential late effects are of concern as cardiovascular pathology can negatively impact quality of life and prognosis in cancer survivors, particularly when additional cardiovascular risk factors are present...
January 11, 2019: International Journal of Cardiology
Roberto Carnevale, Gaetano Lanzetta, Giuseppe Biondi-Zoccai, Giacomo Frati
No abstract text is available yet for this article.
April 1, 2019: International Journal of Cardiology
Amir Abbas Mahabadi, Christoph Rischpler
Cancer therapy may lead to cardiovascular complications and can promote each aspect of cardiac disease manifestation, such as vascular disease including coronary heart disease, myocardial diseases including heart failure, structural heart diseases including valvular heart diseases, and rhythm disorders. All potential complications of cancer therapy onto the cardiovascular system require imaging for diagnostic workup as well as monitoring of therapy. Transthoracic echocardiography (TTE) is the most frequently used tool for assessment of cardiac function during or after cancer therapy in daily clinical routine...
December 2018: Journal of Thoracic Disease
Lucia Venneri, Giacomo Zoppellaro, Rajdeep S Khattar
Cardio-oncology is a rapidly growing field aimed at improving the quality of care of cancer patients by preventing and monitoring cardiovascular complications resulting from cancer treatment. Cardiac imaging, and in particular, transthoracic echocardiography, plays an essential
role in the baseline assessment and serial follow-up of cardio-oncology patients. Areas covered: This review article discusses the role of cardiac imaging with a focus on advanced echocardiography for the detection and management of cancer therapy related cardiovascular complications, in particular, left ventricular dysfunction and heart failure...
April 2018: Expert Review of Cardiovascular Therapy
Nathalie Donis, Cécile Oury, Marie Moonen, Patrizio Lancellotti
Available data indicate that survivors of breast cancer and Hodgkin lymphoma who received mediastinal radiotherapy are at increased risk of developing radiation-induced cardiovascular diseases (RICVD) one or two decades after treatment. Although the risk with modern radiation treatment is likely to be lower in these patient groups, cardiotoxicity is still observed in a subset of patients. In addition, radiation-associated cardiovascular complications can, in the future, extend to other groups of cancer patients who are treated for tumors that are localized near the heart...
April 2018: Expert Opinion on Pharmacotherapy
Paaladinesh Thavendiranathan
No abstract text is available yet for this article.
August 2018: JACC. Cardiovascular Imaging
Anita Vohra, Aarti Asnani
PURPOSE OF REVIEW: In this article, we review current and emerging approaches to biomarker discovery to facilitate early diagnosis of cancer therapy-associated cardiovascular toxicity. RECENT FINDINGS: Although small studies have demonstrated an association between established biomarkers of cardiac injury (troponins and brain natriuretic peptide) and acute or subacute cardiotoxicity, there is insufficient evidence to support their use in routine clinical care. Preclinical studies to define the molecular mechanisms of cardiotoxicity, as well as the use of unbiased "omics" techniques in small patient cohorts, have yielded promising candidate biomarkers that have the potential to enrich current risk stratification algorithms...
May 25, 2018: Current Cardiology Reports
Sarju Ganatra, Salim S Hayek
No abstract text is available yet for this article.
June 26, 2018: Journal of the American College of Cardiology
Vincent A Pallazola, Joseph C Murray, Munjid Al Harthy, Stefan L Zimmerman, Jonathan Webster, Lukasz P Gondek
No abstract text is available yet for this article.
March 2018: American Journal of Hematology
2017-12-04 15:50:34
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"